Acrivon Therapeutics, Inc. — Director's Dealing 2026

Feb 18, 2026

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Acrivon Therapeutics, Inc. (ACRV)
CIK: 0001781174
Period of Report: 2026-02-14

Reporting Person: Gamelin Erick (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2026-02-14	Common Stock	F	471	$1.63	Disposed	14812	Direct

Footnotes

F1: Shares withheld by the Issuer to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.